Cargando…
Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban
Direct oral anticoagulants (DOACs) are used for many conditions where anticoagulation is needed such as non-valvular atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE). These novel agents have become popular since they do not require monitoring of therapeutic levels and ther...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681851/ https://www.ncbi.nlm.nih.gov/pubmed/31413784 http://dx.doi.org/10.14740/cr902 |
_version_ | 1783441782916251648 |
---|---|
author | Cinelli, Michael Uddin, Asif Duka, Ilirjana Soomro, Armaghan Tamburrino, Frank Ghavami, Foad Lafferty, James |
author_facet | Cinelli, Michael Uddin, Asif Duka, Ilirjana Soomro, Armaghan Tamburrino, Frank Ghavami, Foad Lafferty, James |
author_sort | Cinelli, Michael |
collection | PubMed |
description | Direct oral anticoagulants (DOACs) are used for many conditions where anticoagulation is needed such as non-valvular atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE). These novel agents have become popular since they do not require monitoring of therapeutic levels and there is a lower risk of certain bleeding complications when compared to warfarin. However, the efficacy and side effect profile of these agents have not been widely studied in certain patient cohorts, namely cancer patients and patients on immunomodulators or hormone analogs. We present a case of a patient with a history of malignancy and autoimmune disease who developed pericardial and pleural effusions shortly after initiating apixaban for treatment of a PE. In addition, we aim to increase awareness of the role that the newly available reversal agents for anticoagulants would offer in the acute management of hemorrhagic pericardial and pleural effusions caused by DOACs in patients with and without malignancy. |
format | Online Article Text |
id | pubmed-6681851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-66818512019-08-14 Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban Cinelli, Michael Uddin, Asif Duka, Ilirjana Soomro, Armaghan Tamburrino, Frank Ghavami, Foad Lafferty, James Cardiol Res Case Report Direct oral anticoagulants (DOACs) are used for many conditions where anticoagulation is needed such as non-valvular atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE). These novel agents have become popular since they do not require monitoring of therapeutic levels and there is a lower risk of certain bleeding complications when compared to warfarin. However, the efficacy and side effect profile of these agents have not been widely studied in certain patient cohorts, namely cancer patients and patients on immunomodulators or hormone analogs. We present a case of a patient with a history of malignancy and autoimmune disease who developed pericardial and pleural effusions shortly after initiating apixaban for treatment of a PE. In addition, we aim to increase awareness of the role that the newly available reversal agents for anticoagulants would offer in the acute management of hemorrhagic pericardial and pleural effusions caused by DOACs in patients with and without malignancy. Elmer Press 2019-08 2019-07-31 /pmc/articles/PMC6681851/ /pubmed/31413784 http://dx.doi.org/10.14740/cr902 Text en Copyright 2019, Cinelli et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Cinelli, Michael Uddin, Asif Duka, Ilirjana Soomro, Armaghan Tamburrino, Frank Ghavami, Foad Lafferty, James Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title | Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title_full | Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title_fullStr | Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title_full_unstemmed | Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title_short | Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban |
title_sort | spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681851/ https://www.ncbi.nlm.nih.gov/pubmed/31413784 http://dx.doi.org/10.14740/cr902 |
work_keys_str_mv | AT cinellimichael spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT uddinasif spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT dukailirjana spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT soomroarmaghan spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT tamburrinofrank spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT ghavamifoad spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban AT laffertyjames spontaneoushemorrhagicpericardialandpleuraleffusioninapatientreceivingapixaban |